New eczema drug candidate enters first human safety tests
NCT ID NCT07205081
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This early-stage study tests a new drug called ATTO-3712 in 72 healthy adults and people with atopic dermatitis (eczema). The main goal is to see if the drug is safe and how long it stays in the body. Participants receive either the drug or a placebo and are monitored with clinic visits and symptom diaries.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Altasciences
RECRUITINGMontreal, Quebec, H3P 3P1, Canada
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.